FY2028 EPS Estimates for Tilray Cut by Atb Cap Markets

Tilray Inc (NASDAQ:TLRY) – Analysts at Atb Cap Markets dropped their FY2028 EPS estimates for Tilray in a research report issued to clients and investors on Monday, December 16th. Atb Cap Markets analyst F. Gomes now forecasts that the company will post earnings per share of $0.01 for the year, down from their prior estimate of $0.06. The consensus estimate for Tilray’s current full-year earnings is ($0.14) per share.

Separately, Roth Mkm lowered their target price on Tilray from $2.00 to $1.75 and set a “neutral” rating for the company in a research note on Friday, October 11th.

Tilray Stock Performance

TLRY stock opened at $1.16 on Wednesday. Tilray has a 1-year low of $1.15 and a 1-year high of $2.97. The business’s 50-day moving average price is $1.45 and its two-hundred day moving average price is $1.66. The firm has a market cap of $1.05 billion, a PE ratio of -4.30 and a beta of 2.08. The company has a current ratio of 2.47, a quick ratio of 1.57 and a debt-to-equity ratio of 0.08.

Tilray (NASDAQ:TLRY) last released its quarterly earnings data on Thursday, October 10th. The company reported ($0.04) EPS for the quarter, meeting analysts’ consensus estimates of ($0.04). The business had revenue of $200.00 million during the quarter, compared to the consensus estimate of $218.70 million. Tilray had a negative return on equity of 2.00% and a negative net margin of 26.79%. The firm’s revenue was up 13.0% on a year-over-year basis. During the same quarter in the prior year, the company posted ($0.10) earnings per share.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently made changes to their positions in TLRY. BNP Paribas Financial Markets boosted its holdings in shares of Tilray by 1,314.1% during the third quarter. BNP Paribas Financial Markets now owns 1,819,494 shares of the company’s stock worth $3,202,000 after acquiring an additional 1,690,827 shares during the period. Point72 Asset Management L.P. acquired a new stake in Tilray during the 3rd quarter worth approximately $1,348,000. Bank of Montreal Can boosted its stake in Tilray by 19.6% in the 2nd quarter. Bank of Montreal Can now owns 2,169,100 shares of the company’s stock valued at $3,622,000 after purchasing an additional 355,778 shares during the period. Creative Planning grew its holdings in Tilray by 36.6% in the 3rd quarter. Creative Planning now owns 141,921 shares of the company’s stock valued at $250,000 after buying an additional 38,054 shares in the last quarter. Finally, The Manufacturers Life Insurance Company increased its position in Tilray by 11.5% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 682,478 shares of the company’s stock worth $1,131,000 after buying an additional 70,605 shares during the period. 9.35% of the stock is currently owned by institutional investors.

Insider Activity

In related news, CFO Carl A. Merton purchased 26,000 shares of Tilray stock in a transaction that occurred on Friday, November 15th. The stock was purchased at an average cost of $1.36 per share, with a total value of $35,360.00. Following the completion of the transaction, the chief financial officer now owns 26,000 shares of the company’s stock, valued at approximately $35,360. This trade represents a ? increase in their position. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Corporate insiders own 0.87% of the company’s stock.

About Tilray

Tilray, Inc engages in the research, cultivation, processing, and distribution of medical cannabis. The company offers its products in Argentina, Australia, Canada, Chile, Croatia, Cyprus, the Czech Republic, Germany, New Zealand, and South Africa. Tilray, Inc is headquartered in Canada.